Physician

Oncology

Martin N. Raber is an expert in the field of Oncology. Martin Raber is a published doctor and has 69 publications published. The lastest was: 'Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors.'

Publications

---

• Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset.
• A phase II study to evaluate the efficacy and toxicity of oxaliplatin in combination with gemcitabine in carcinoma of unknown primary.
• Prospective Gene Signature Study Using microRNA to Identify the Tissue of Origin in Patients with Carcinoma of Unknown Primary.
• Carcinoma of unknown primary origin: on the cusp of a new era.
• Gene expression profiling in Cancers of unknown primary.
• Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation.
• Metastatic patterns in adenocarcinoma.
• Carcinoma of unknown primary with a colon-Cancer profile-changing paradigm and emerging definitions.
• Classification and regression tree Analysis of 1000 consecutive patients with unknown primary carcinoma.
• Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma?
• Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin.
• Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients.
• Detection of primary breast Cancer presenting as metastatic carcinoma of unknown primary origin by 111In-pentetreotide scan.
• Unknown primary tumors metastatic to Liver.
• Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.
• Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin.
• Phase II study of cisplatin, 5-fluorouracil and folinic acid in patients with carcinoma of unknown primary origin.
• Are time or intensity factors important to the definition of metastases of unknown origin?
• A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.
• Phase II study of topotecan in patients with advanced non-small-cell lung Cancer previously untreated with chemotherapy.
• Phase I trial of 1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU) terminated by severe neurologic toxicity.
• Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial Ovarian carcinoma.
• Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid Tumors.
• Phase I clinical trial of cisplatin given i.v. with 5-fluorouracil and high-dose folinic acid.
• The biology of unknown primary Tumors.
• A pilot-study of Paclitaxel in previously treated patients with metastatic unknown primary carcinomas.
• Phase I trial of semustine plus weekly fluorouracil and high-dose leucovorin calcium in patients with advanced coloRectal cancer.
• Design and results of phase I Cancer clinical trials: three-year experience at M.D. Anderson Cancer Center.
• Errors in Cancer diagnosis: current understanding and future directions.
• Phase I evaluation of all-trans retinoic acid with and without ketoconazole in adults with solid Tumors.
• Phase II clinical trial of didemnin B in previously treated small cell lung Cancer.
• Phase I clinical evaluation of [SP-4-3(R)]-[1,1-cyclobutanedicarboxylato(2-)](2-methyl-1,4- butanediamine-N,N1) platinum in patients with metastatic solid Tumors.
• Phase I evaluation of all-trans-retinoic acid in adults with solid Tumors.
• Phase I-II study: triciribine (tricyclic nucleoside phosphate) for metastatic breast Cancer.
• A patient's perspective on Cancer-related fatigue.
• Phase II clinical and pharmacological study of didemnin B in patients with metastatic breast Cancer.
• A phase II trial of taxol in metastatic melanoma.
• Phase I trial and clinical pharmacology of elsamitrucin.
• Clinical pharmacology of combined oral uracil and ftorafur.
• Ifosfamide with mesna uroprotection in the management of lung Cancer.
• Clinical pharmacology of 11-acetyl-8-carbamoyloxymethyl-4-formyl-14-oxa-1,11-diazatetracyclo (7.4.1.0(2,7).0(10,12) tetradeca-2,4,6-trien-6,9-diyl diacetate (FK 973).
• Phase-I and phase-ii trials of a laboratory-derived synergistic combination of Cisplatin and 2''-deoxy-5-azacytidine.
• Intrapleural etoposide for malignant effusion.
• Phase I clinical investigation of benzisoquinolinedione.
• Clinical pharmacokinetics of ifosfamide in combination with N-acetylcysteine.
• The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere).
• Phase I trial of a 72-h continuous-infusion schedule of fazarabine.
• Phase I evaluation of thio-TEPA in combination with cisplatin for advanced gynecologic Malignancies.
• Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II).
• Unknown primary Tumors.
• Phase I trial of FK973: description of a delayed vascular leak syndrome.
• Comprehensive criteria for assessing therapy-induced toxicity.
• Multiple primary malignant Tumors.
• Phase I clinical trial and pharmacokinetic evaluation of 4''-0-tetrahydropyranyladriamycin (THP-adriamycin).
• Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma.
• Phase II study of taxol in patients with untreated advanced non-small-cell lung Cancer.
• Phase II clinical trial of 4'-O-tetrahydropyranyl-adriamycin (THP-adriamycin) in recurrent squamous cell carcinoma of the head and neck.
• Phase II trial of intravenous 6-thioguanine for unresectable or metastatic non-small cell bronchogenic carcinoma.
• Phase II trial of taxol, an active drug in the treatment of metastatic breast Cancer.
• Phase II trial of 5,6-dihydro-5-azacytidine in pleural malignant mesothelioma.
• Phase I/II clinical trial of didemnin B in non-small-cell lung Cancer: neuromuscular toxicity is dose-limiting.
• Phase I studies of trimetrexate using single and weekly dose schedules.
• Phase I study of recombinant methionyl human consensus interferon (r-metHuIFN-Con1).
• Clinical pharmacology of 1-beta-D-arabinofuranosyl-5-azacytosine (fazarabine) following 72-hour infusion.
• Flow-cytometric Analysis of DNA content in postmortem tissue.
• Comparison of single preoperative oral rufloxacin versus perioperative ciprofloxacin as prophylactic agents in transurethral surgery.
• Analysis of pleural effusions using automated flow cytometry.
• Anaplastic myeloma with massive extramedullary involvement. Report of two cases.

Schools

---

• Catholic University Of Louvain

• Dalhousie University

• MD Anderson Hospital

Conditions Treated

---

• Anal and Rectal Cancer
• Anemia
• Breast Cancer
• ColoRectal Cancer
• View All

Doctors Specialties

---

• Medical Oncology
• Oncology

Accepted Insurances

---

Education

---

• University of Texas Health Science Center
• Catholic University of Leuven

Hospital

---

• University of Texas M.D. Anderson Cancer Center

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Dr. Kathy Sam, MD This Doctor is OpenDoctor Recommended.
	Dr. Larry W. Kwak, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Shirisha Reddy, MD This Doctor is OpenDoctor Recommended.
	Dr. Francesco Turturro, MD This Doctor is OpenDoctor Recommended.
	Dr. Katherine M. Pisters, MD This Doctor is OpenDoctor Recommended.
	Dr. Banu K. Arun, MD This Doctor is OpenDoctor Recommended.
	Dr. Eric Jonasch, MD This Doctor is OpenDoctor Recommended.
	Dr. Michael J. Fisch, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Jorge E. Romaguera, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog